

23 FEBRUAR 2000

Claims;

1. An oil-in-water lipid emulsion for delivering biologically active material selected
5 from the group consisting of DNA, RNA, antisense nucleic acid, ribosome, polynucleotide and oligonucleotide, comprising: 2-30% of non-triglyceride oil; 0.01-20% of one or more cationic lipid transfection agent; and, water to 100%.
2. Solid-lipid nanoparticles for delivering biologically active material selected from
10 the group consisting of DNA, RNA, antisense nucleic acid, ribosome, polynucleotide and oligonucleotide, comprising: 2-30% of fat of triglycerides having 10-18 carbons in each hydrophobic tail or ethyl stearate; 0.01-20% of one or more cationic lipid transfection agent; and, water to 100%.
- ✓
15 3. Deleted
- ✓
4. Deleted
5. A method of preparing an oil-in-water lipid emulsion for delivering biologically
active material selected from the group consisting of DNA, RNA, antisense
20 nucleic acid, ribosome, polynucleotide and oligonucleotide, comprising: a) a first step of preparing an aqueous phase by mixing 0.01-20% of one or more cationic lipid transfection agent with water and b) a second step of preparing emulsion of said aqueous phase with 2-30% of non-triglyceride oil.
6. A method of preparing solid lipid nanoparticles for delivering biologically active
25 material selected from the group consisting of DNA, RNA, antisense nucleic

20. FEBRUAR 2000

SEP 30 1997

acid, ribosome, polynucleotide and oligonucleotide, comprising: a) a first step of preparing an aqueous phase by mixing 0.01-20% of one or more cationic lipid transfection agent with water and b) a second step of mixing said aqueous phase with 2-30% of fat of triglycerides having 10-18 carbons in each hydrophobic tail or ethyl stearate.

7. Deleted

8. Deleted

9. The emulsion according to claim 1, further comprising 0.01-10% of a hydrophilic polymer or hydrophilic polymeric lipid.

10. The emulsion according to claim 1, wherein the non-triglycerides is squalene or squalane.

11. The emulsion according to any of claims 1, 9 or 10, further comprising a phospholipid or a non-ionic surfactant.

12. The emulsion according to claim 1, wherein the cationic lipid transfection agent is selected from the group consisting of:

1,2-dimyristoyl-3-trimethylammonium-propane,

1,2-dipalmitoyl-3-trimethylammonium-propane,

1,2-distearoyl-3-trimethylammonium-propane,

1,2-dioleoyl-3-trimethylammonium-propane,

1,2-dimyristoyl-3-dimethylammonium-propane,

00744510001

SUB
A1

1,2-dipalmitoyl-3-dimethylammonium-propane,

28. FEBRUAR 2000

1,2-dilauroyl-3-dimethylammonium-propane,

1,2-distearoyl-3-dimethylammonium-propane,

1,2-dipalmitoyl-3-trimethylammonium-propane,

5 N-[1-(1,2-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride,

1,2-dioleoyl-3-ethylphosphocholine, and other cationic lipids.

13. The emulsion according to any of claims 1, 9, or 10, further comprising glycerol or fusogenic peptides.

14. The emulsion according to claim 13, wherein the fusogenic peptide is polyethylene glycol of MW.500-1000 or HA gp 41. ?

15. The emulsion according to claim 9, wherein the hydrophilic polymer is selected from the group consisting of polyoxyethylene, polyethyloxazoline and polyethyleneglycol.

16. The emulsion according to claim 11, wherein the phospholipid is selected from the group consisting of phosphatidylcholin, phosphatidylethanolamine, phosphatidylserine, diacetylenic phospholipid and derivative thereof and the non-ionic surface active agent is selected from the group consisting of poloxamer, sorbitan ester, polyoxyethylene-sorbitan fat acid ester and polyoxyethylene ethers.

17. The emulsion according to any of claims, 1, 9, or 10, further comprising 1,2-dioleoyl-sn-3-phosphatidylethanolamine, diolein, fatty alcohol, cholesterol

SUB
A2

SUB
A3

09744751.050101

AM 24 APR 2001

28. FEBRUAR 2000

ANT 34888T
SUB
A3
CONV.

or bile salt.

18. The solid lipid nanoparticles according to claim 2, further comprising 0.01-10% of a hydrophilic polymer or hydrophilic polymeric lipid.

19. The solid lipid nanoparticles according to claim 2 or 18, further comprising a phospholipid or a non-ionic surfactant.

20. The solid lipid nanoparticle according to claim 2, wherein the cationic lipid transfection agent is selected from the group consisting of:

1,2-dimyristoyl-3-trimethylammonium-propane,

1,2-dipalmitoyl-3-trimethylammonium-propane,

1,2-distearoyl-3-trimethylammonium-propane,

1,2-dioleoyl-3-trimethylammonium-propane,

1,2-dimyristoyl-3-dimethylammonium-propane,

1,2-dipalmitoyl-3-dimethylammonium-propane,

1,2-dilauroyl-3-dimethylammonium-propane,

1,2-distearoyl-3-dimethylammonium-propane,

1,2-dipalmitoyl-3-trimethylammonium-propane,

N-[1-(1,2-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride,

1,2-dioleoyl-3-ethylphosphocholine, and other cationic lipids.

21. The solid lipid nanoparticles according to claim 2 or 18, further

SUB
A4

09744751-060101

SUB
A5

AM 34 MET
SUB
A5
CON't

P KR 99 / 00414

28. FEBRUAR 2000

comprising glycerol or fusogenic peptides.

22. The solid lipid nanoparticles according to claim 21, wherein the fusogenic peptide is polyethylene glycol of MW.500-1000 or HA gp 41.

23. The solid lipid nanoparticles according to claim 18, wherein the hydrophilic polymer is selected from the group consisting of polyoxyethylene, polyethyloxazoline and polyethyleneglycol.

24. The solid lipid nanoparticles accordign to claim 19, wherein the phospholipid is selected from the group consisting of phosphatidylcholin, phosphatidylethanolamine, phosphatidylserine, diacetylenic phospholipid and derivative thereof and the non-ionic surface active agent is selected from the group consisting of poloxamer, sorbitan ester, polyoxyethylene-sorbitan fat acid ester and polyoxyethylene ethers.

25. The solid lipid nanoparticles according to claim 2 or 18, further comprising 1,2-dioleoyl-sn-3-phosphatidylethanolamine, diolein, fatty alcohol, cholesterol or bild salt.

26. Deleted.

27. Deleted.

28. Deleted.

29. Deleted.

30. Deleted.

31. Deleted.

0974751-060107

SUB
A6

ART 34 PART

PCT/AR 99 / 00414

28 FEBRUAR 2000

- 5 32. Deleted. ✓
33. Deleted. ✓
34. Deleted. ✓
35. Deleted. ✓
36. Deleted. ✓
37. Deleted. ✓
38. Deleted. ✓
39. Deleted. ✓
40. Deleted. ✓
- 10 41. Deleted. ✓
42. Deleted. ✓
43. Deleted. ✓
44. Deleted. ✓
45. Deleted. ✓
- 15 46. Deleted. ✓
47. Deleted. ✓
48. Deleted. ✓
49. Deleted. ✓

09744751-060301
FOR 090 "T524460"

ART 34 AMDT

PCT/ KR 99 / 00414

25 SEPTEMBER 2000

SUB
A7

✓
50. Deleted.

✓
51. Deleted.

52. A complex of the emulsion according to any of claims 1, 9 to 17 and a biologically active material selected from the group consisting of DNA, RNA, antisense nucleic acid, ribosome, polynucleotide, oligonucleotide.

53. The complex according to claim 52, further comprising glycolipid, lipopeptide, antibody, ligand for receptors or viral protein to target specific cells or organs.

54. The complex according to claim 52 or 53, further comprising protamine sulfate, histone or cationic polymer.

55. The complex according to claim 54, wherein cationic polymer is polylysine.

56. The complex according to claim 52, further comprising monovalent or multivalent salt.

57. The complex according to claim 53, wherein the cell is selected from the group consisting of white blood cells, fibroblasts, cancer cells, cells infected with virus, epithelial cells, endothelial cells, muscle cells, liver cells, endocrine cells, neural cells, dermal cells, germ cells, oocytes, sperms, hematopoietic cells, fetal cells, M cells, Langerhans islet cells, macrophages, plant cells, animal cells, and immortalized cell lines.

58. The complex according to claim 52, wherein the complex is to be transferred to cells via intravenous, intramuscular, intratracheal, intranasal,

09-25 17:06 MON
SUB
A8

ATT 24 14:01

PC KR 99 / 00 4 1 4

25 SEPTEMBER 2000

subcutaneous, parenteral or topical administration or via direct administration to a specific organ.

59. Deleted

60. The complex according to claim 52, further comprising lipophilic or
5 amphiphilic drug in an oil phase, wherein the lipophilic or amphiphilic drug is
selected from the group consisting of antivirals, steroidal anti-inflammatory
drugs, non-steroidal anti-inflammatory drugs, antibiotics, antifungals, vitamins,
hormones, retinoic acid, prostaglandins, prostacyclins, anticancer drugs,
antimetabolic drugs, miotics, cholinergics, adrenergic antagonists,
10 anticonvulsants, antianxiety agents, major tranquilizers, antidepressants,
anesthetics, analgesics, anabolic steroids, estrogens, progesterones,
glycosaminoglycans, polynucleotides, immunosuppressants and
immunostimulants.

61. The complex according to claim 60 wherein the anticancer drug is taxol,
15 paclitaxel or flurourcil.

62. A complex of the solid lipid nanoparticles according to any of claims 2, 12
to 19 with a biologically active material selected from the group consisting of
DNA, RNA, antisense nucleic acid, ribosome, polynucleotide and
oligonucleotide.

63. The complex according to claim 62, further comprising glycolipid,
20 lipopeptide, antibody, ligand for receptors or viral protein to target specific cells
or organs.

64. The complex according to claims 62 or 63, further comprising protamine

09/11/01 15:24:01

SUB
A9

SUB
A10

ATT 34 SUB
A10
CON't.

PCT/ KR 99 / 00 4 1 4

25. SEPTEMBER 2000

sulfate, histone or cationic polymer.

65. The complex according to claim 64, wherein the cationic polymer is polylysine.

66. The complex according to claim 62, further comprising monovalent or multivalent salt.

67. The complex according to claim 63, wherein the cell is selected from the group consisting of white blood cells, fibroblasts, cancer cells, cells infected with virus, epithelial cells, endothelial cells, muscle cells, liver cells, endocrine cells, neural cells, dermal cells, germ cells, oocytes, sperms, hematopoietic cells, fetal cells, M cells, Langerhans islet cells, macrophages, plant cells, animal cells, and immortalized cell lines.

68. The complex according to claim 62, wherein the complex is to be transferred to cells via intravenous, intramuscular, intratracheal, intranasal, subcutaneous, parenteral or topical administration or via direct administration to a specific organ.

69. The complex according to any of claims 62 to 68, further comprising lipophilic or amphiphilic drug in the fat, wherein the lipophilic or amphiphilic drug is selected from the group consisting of antivirals, steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, antibiotics, antifungals, vitamins, hormones, retinoic acid, prostaglandins, prostacyclins, anticancer drugs, antimetabolic drugs, mitotics, cholinergics, adrenergic antagonists, anticonvulsants, antianxiety agents, major tranquilizers, antidepressants, anesthetics, analgesics, anabolic steroids, estrogens, progesterones,

09744751-060101

SUB
A11

AM 341401
SUB
A
CON't.

KR 99 / 00414

28. FEBRUAR 2000

glycosaminoglycans,
immunostimulants.

polynucleotides,

immunosuppressants and

70. The complex according to claim 69, wherein the anticancer drug is taxol, paclitaxel or fluorouracil.

5 71. The method according to claim 5, wherein the aqueous phase further comprises 0.01-10% of a hydrophilic polymer or hydrophilic polymeric lipid.

72. The method according to claim 6, wherein the aqueous phase further comprises 0.01-10% of a hydrophilic polymer or hydrophilic polymeric lipid.

73. Deleted.

10 74. Deleted

75. The method according to claim 5, wherein the cationic lipid transfection agent is added in the oil phase instead of in an aqueous phase.

76. The method according to claim 6, wherein the cationic lipid transfection agent is added in melted fat instead of in an aqueous phase.

15 77. Deleted.

78. Deleted.

79. The complex according to claim 60, wherein the immunosuppressant is cyclosporin A.

20 80. The complex according to claim 69, wherein the immunosuppressant is cyclosporin A.